Nontuberculous Mycobacterial Infections in Cystic Fibrosis

Clinics in Chest Medicine

Volumn 37, Issue 1, 2016, Pages 83-96

  Martiniano, Stacey L ^a   Nick, Jerry A ^a,b   Daley, Charles L ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF MEDICINE   (United States)

Author keywords

Cystic fibrosis; Mycobacterium abscessus complex; Mycobacterium avium complex; Nontuberculous mycobacteria

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFOXITIN; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DOXYCYCLINE; ETHAMBUTOL; IMIPENEM; LINEZOLID; MACROLIDE; MINOCYCLINE; MOXIFLOXACIN; RIFAMYCIN; TIGECYCLINE; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTIFICIAL VENTILATION; ATYPICAL MYCOBACTERIOSIS; BACTERIAL TRANSMISSION; BACTERIUM DETECTION; BACTERIUM ISOLATION; BROTH DILUTION; COMORBIDITY; CYSTIC FIBROSIS; DIET THERAPY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MONITORING; DRUG SAFETY; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; FOLLOW UP; HIGH RISK POPULATION; HUMAN; INFECTION RISK; LABORATORY TEST; LUNG FUNCTION TEST; LUNG SURGERY; LUNG TRANSPLANTATION; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM BOLETTII; MYCOBACTERIUM MASSILIENSE; NONHUMAN; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; REVIEW; RISK FACTOR; SPUTUM CULTURE; TREATMENT DURATION; TREATMENT RESPONSE; ATYPICAL MYCOBACTERIUM; COMPLICATION; HEALTH; ISOLATION AND PURIFICATION; MICROBIOLOGY; MORBIDITY; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; TRENDS;

CYSTIC FIBROSIS; GLOBAL HEALTH; HUMANS; MORBIDITY; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; NONTUBERCULOUS MYCOBACTERIA;

EID: 84959334283     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2015.11.001     Document Type: Review

References (112)

1. Roux A.-L., Catherinot E., Ripoll F., Jean-Louis Herrmann for the OMAG, et al. Multicenter study of prevalence of nontuberculous mycobacteria in patients with cystic fibrosis in France. J Clin Microbiol 2009, 47:4124-4128.
2. Esther C.R., Esserman D.A., Gilligan P., et al. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibros 2010, 9:117-123.
3. Qvist T., Pressler T., Hoiby N., et al. Shifting paradigms of nontuberculous mycobacteria in cystic fibrosis. Respir Res 2014, 15:41.
4. Griffith D.E., Aksamit T., Brown-Elliott B.A., et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007, 175:367-416.
5. Prevots D.R., Marras T.K. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. Clin Chest Med 2015, 36:13-34.
6. Andre E., Degraux J., Simon A., et al. Absence of non-tuberculous mycobacteria recovery in sputum of cystic fibrosis patients despite adequate decontamination: a possible role of specific antimicrobial therapy used in our centre. Clin Microbiol Infect 2010, 16:S33-S34.
7. Torrens J.K., Dawkins P., Conway S.P., et al. Non-tuberculous mycobacteria in cystic fibrosis. Thorax 1998, 53:182-185.
8. Sermet-Gaudelus I., Le Bourgeois M., Pierre-Audigier C., et al. Mycobacterium abscessus and children with cystic fibrosis. Emerg Infect Dis 2003, 9:1587-1591.
9. Olivier K.N., Weber D.J., Wallace R.J., Nontuberculous Mycobacteria in Cystic Fibrosis Study Group, et al. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003, 167:828-834.
10. Aitken M.L., Burke W., McDonald G., et al. Nontuberculous mycobacterial disease in adult cystic fibrosis patients. Chest 1993, 103:1096-1099.
11. Valenza G., Tappe D., Turnwald D., et al. Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis. J Cyst Fibros 2008, 7:123-127.
12. Adjemian J., Olivier K.N., Prevots D.R. Nontuberculous mycobacteria among patients with cystic fibrosis in the United States: screening practices and environmental risk. Am J Respir Crit Care Med 2014, 190:581-586.
13. Adjemian J., Olivier K.N., Seitz A.E., et al. Spatial clusters of nontuberculous mycobacterial lung disease in the United States. Am J Respir Crit Care Med 2012, 186(6):553-558.
14. Leung J.M., Olivier K.N. Nontuberculous mycobacteria in patients with cystic fibrosis. Semin Respir Crit Care Med 2013, 34:124-134.
15. Qvist T., Gilljam M., Jonsson B., Scandinavian Cystic Fibrosis Study Consortium (SCFSC), et al. Epidemiology of nontuberculous mycobacteria among patients with cystic fibrosis in Scandinavia. J Cyst Fibros 2015, 14:46-52.
16. Bar-On O., Mussaffi H., Mei-Zahav M., et al. Increasing nontuberculous mycobacteria infection in cystic fibrosis. J Cyst Fibros 2015, 14:53-62.
17. Raidt L., Idelevich E.A., Dubbers A., et al. Increased prevalence and resistance of important pathogens recovered from respiratory specimens of cystic fibrosis patients during a decade. Pediatr Infect Dis J 2015, 34:700-705.
18. Adjemian J., Olivier K.N., Seitz A.E., et al. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med 2012, 185:881-886.
19. Prevots D.R., Shaw P.A., Strickland D., et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med 2010, 182:970-976.
20. Rodman D.M., Polis J.M., Heltshe S.L., et al. Late diagnosis defines a unique population of long-term survivors of cystic fibrosis. Am J Respir Crit Care Med 2005, 171:621-626.
21. Hjelte L., Petrini B., Kallenius G., et al. Prospective study of mycobacterial infections in patients with cystic fibrosis. Thorax 1990, 45:397-400.
22. Kilby J.M., Gilligan P.H., Yankaskas J.R., et al. Nontuberculous mycobacteria in adult patients with cystic fibrosis. Chest 1992, 102:70-75.
23. Esther C.R., Henry M.M., Molina P.L., et al. Nontuberculous mycobacterial infection in young children with cystic fibrosis. Pediatr Pulmonol 2005, 40:39-44.
24. Seddon P., Fidler K., Raman S., et al. Prevalence of nontuberculous mycobacteria in cystic fibrosis clinics, United Kingdom, 2009. Emerg Infect Dis 2013, 19:1128-1130.
25. Pierre-Audigier C., Ferroni A., Sermet-Gaudelus I., et al. Age-related prevalence and distribution of nontuberculous mycobacterial species among patients with cystic fibrosis. J Clin Microbiol 2005, 43:3467-3470.
26. Levy I., Grisaru-Soen G., Lerner-Geva L., et al. Multicenter cross-sectional study of nontuberculous mycobacterial infections among cystic fibrosis patients, Israel. Emerg Infect Dis 2008, 14:378-384.
27. Catherinot E., Roux A.L., Vibet M.A., OMA Group, et al. Mycobacterium avium and Mycobacterium abscessus complex target distinct cystic fibrosis patient subpopulations. J Cyst Fibros 2013, 12:74-80.
28. Fauroux B., Delaisi B., Clement A., et al. Mycobacterial lung disease in cystic fibrosis: a prospective study. Pediatr Infect Dis J 1997, 16:354-358.
29. Hjelt K., Hojlyng N., Howitz P., et al. The role of mycobacteria other than tuberculosis (MOTT) in patients with cystic fibrosis. Scand J Infect Dis 1994, 26:569-576.
30. Keating C.L., Liu X., Dimango E.A. Classic respiratory disease but atypical diagnostic testing distinguishes adult presentation of cystic fibrosis. Chest 2010, 137:1157-1163.
31. Nick J.A., Chacon C.S., Brayshaw S.J., et al. Effects of gender and age at diagnosis on disease progression in long-term survivors of cystic fibrosis. Am J Respir Crit Care Med 2010, 182:614-626.
32. Chalermskulrat W., Sood N., Neuringer I.P., et al. Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation. Thorax 2006, 61:507-513.
33. Burgel P., Morand P., Audureau E., et al. Azithromycin and the risk of nontuberculous mycobacteria in adults with cystic fibrosis. Pediatr Pulmonology 2011, 46:328.
34. Ager S., O'Brien C., Spencer D.A., et al. A retrospective review of non-tuberculous mycobacteria in paediatric cystic fibrosis patients at a regional centre. J Cyst Fibros 2011, 10:S36.
35. Paugam A., Baixench M.-T., Demazes-Dufeu N., et al. Characteristics and consequences of airway colonization by filamentous fungi in 201 adult patients with cystic fibrosis in France. Med Mycol 2010, 48(Suppl 1):S32-S36.
36. Mussaffi H., Rivlin J., Shalit I., et al. Nontuberculous mycobacteria in cystic fibrosis associated with allergic bronchopulmonary aspergillosis and steroid therapy. Eur Respir J 2005, 25:324-328.
37. Evans J.T., Ratnaraja N., Gardiner S., et al. Mycobacterium abscessus in cystic fibrosis: what does it all mean?. Clin Microbiol Infect 2011, 17:S602.
38. Falkinham J.O. Surrounded by mycobacteria: nontuberculous mycobacteria in the human environment. J Appl Microbiol 2009, 107:356-367.
39. Giron R.M., Maiz L., Barrio I., et al. Nontuberculous mycobacterial infection in patients with cystic fibrosis: a multicenter prevalence study. Arch Bronconeumol 2008, 44:679-684. [in Spanish].
40. Olivier K.N., Weber D.J., Lee J.-H., Nontuberculous Mycobacteria in Cystic Fibrosis Study Group, et al. Nontuberculous mycobacteria. II: nested-cohort study of impact on cystic fibrosis lung disease. Am J Respir Crit Care Med 2003, 167:835-840.
41. Renna M., Schaffner C., Brown K., et al. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J Clin Invest 2011, 121:3554-3563.
42. Binder A.M., Adjemian J., Olivier K.N., et al. Epidemiology of nontuberculous mycobacterial infections and associated chronic macrolide use among persons with cystic fibrosis. Am J Respir Crit Care Med 2013, 188:807-812.
43. Catherinot E., Roux A.L., Vibet M.A., OMA Group, et al. Inhaled therapies, azithromycin and Mycobacterium abscessus in cystic fibrosis patients. Eur Respir J 2013, 41:1101-1106.
44. Radhakrishnan D.K., Yau Y., Corey M., et al. Non-tuberculous mycobacteria in children with cystic fibrosis: isolation, prevalence, and predictors. Pediatr Pulmonology 2009, 44:1100-1106.
45. Prevots D.R., Adjemian J., Fernandez A.G., et al. Environmental risks for nontuberculous mycobacteria. Individual exposures and climatic factors in the cystic fibrosis population. Ann Am Thorac Soc 2014, 11:1032-1038.
46. Forslow U., Geborek A., Hjelte L., et al. Early chemotherapy for non-tuberculous mycobacterial infections in patients with cystic fibrosis. Acta Paediatr 2003, 92:910-915.
47. Leitritz L., Griese M., Roggenkamp A., et al. Prospective study on nontuberculous mycobacteria in patients with and without cystic fibrosis. Med Microbiol Immunol 2004, 193:209-217.
48. Martiniano S.L., Sontag M.K., Daley C.L., et al. Clinical significance of a first positive nontuberculous mycobacteria culture in cystic fibrosis. Ann Am Thorac Soc 2014, 11:36-44.
49. Martiniano S.L., Nick J.A. Nontuberculous mycobacterial infections in cystic fibrosis. Clin Chest Med 2015, 36:101-115.
50. Whittier S., Olivier K., Gilligan P., et al. Proficiency testing of clinical microbiology laboratories using modified decontamination procedures for detection of nontuberculous mycobacteria in sputum samples from cystic fibrosis patients. The Nontuberculous Mycobacteria in Cystic Fibrosis Study Group. J Clin Microbiol 1997, 35:2706-2708.
51. Bange F.C., Bottger E.C. Improved decontamination method for recovering mycobacteria from patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis 2002, 21:546-548.
52. Whittier S., Hopfer R.L., Knowles M.R., et al. Improved recovery of mycobacteria from respiratory secretions of patients with cystic fibrosis. J Clin Microbiol 1993, 31:861-864.
53. Steingart K.R., Ng V., Henry M., et al. Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis 2006, 6:664-674.
54. Brown-Elliott B.A., Griffith D.E., Wallace R.J. Diagnosis of nontuberculous mycobacterial infections. Clin Lab Med 2002, 22:911-925. vi.
55. Buijtels P.C., Petit P.L. Comparison of NaOH-N-acetyl cysteine and sulfuric acid decontamination methods for recovery of mycobacteria from clinical specimens. J Microbiol Methods 2005, 62:83-88.
56. Floto A, ea. Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of nontuberculous mycobacteria in individuals with cystic fibrosis. Thorax, in press.
57. Bange F.C., Kirschner P., Bottger E.C. Recovery of mycobacteria from patients with cystic fibrosis. J Clin Microbiol 1999, 37:3761-3763.
58. Ferroni A., Vu-Thien H., Lanotte P., et al. Value of the chlorhexidine decontamination method for recovery of nontuberculous mycobacteria from sputum samples of patients with cystic fibrosis. J Clin Microbiol 2006, 44:2237-2239.
59. Preece C.L., Perry A., Gray B., et al. A novel culture medium for isolation of rapidly-growing mycobacteria from the sputum of patients with cystic fibrosis. J Cyst Fibros 2015, [Epub ahead of print].
60. van Ingen J. Microbiological diagnosis of nontuberculous mycobacterial pulmonary disease. Clin Chest Med 2015, 36:43-54.
61. Buchan B.W., Riebe K.M., Timke M., et al. Comparison of MALDI-TOF MS with HPLC and nucleic acid sequencing for the identification of Mycobacterium species in cultures using solid medium and broth. Am J Clin Pathol 2014, 141:25-34.
62. CLSI Susceptibility testing of mycobacteria, nocardia, and other aerobic actinomycetes: approved standard-second edition 2011, CLSI document M24-A2, Clinical and Laboratory Standards Institute, Wayne (PA).
63. Nash K.A., Brown-Elliott B.A., Wallace R.J. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 2009, 53:1367-1376.
64. Doucet-Populaire F., Buriankova K., Weiser J., et al. Natural and acquired macrolide resistance in mycobacteria. Curr Drug Targets Infect Disord 2002, 2:355-370.
65. Griffith D.E., Brown-Elliott B.A., Langsjoen B., et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2006, 174:928-934.
66. Verma N., Spencer D. Disseminated Mycobacterium gordonae infection in a child with cystic fibrosis. Pediatr Pulmonology 2012, 47:517-518.
67. Mulherin D., Coffey M.J., Halloran D.O., et al. Skin reactivity to atypical mycobacteria in cystic fibrosis. Respir Med 1990, 84:273-276.
68. Ngan G.J., Ng L.M., Jureen R., et al. Development of multiplex PCR assays based on the 16S-23S rRNA internal transcribed spacer for the detection of clinically relevant nontuberculous mycobacteria. Lett Appl Microbiol 2011, 52:546-554.
69. Leung K.L., Yip C.W., Cheung W.F., et al. Development of a simple and low-cost real-time PCR method for the identification of commonly encountered mycobacteria in a high throughput laboratory. J Appl Microbiol 2009, 107:1433-1439.
70. Devine M., Moore J.E., Xu J., et al. Detection of mycobacterial DNA from sputum of patients with cystic fibrosis. Ir J Med Sci 2004, 173:96-98.
71. Oliver A., Maiz L., Canton R., et al. Nontuberculous mycobacteria in patients with cystic fibrosis. Clin Infect Dis 2001, 32:1298-1303.
72. Ferroni A., Sermet-Gaudelus I., Le Bourgeois M., et al. Measurement of immunoglobulin G against mycobacterial antigen A60 in patients with cystic fibrosis and lung infection due to Mycobacterium abscessus. Clin Infect Dis 2005, 40:58-66.
73. Qvist T., Pressler T., Taylor-Robinson D., et al. Serodiagnosis of Mycobacterium abscessus complex infection in cystic fibrosis. Eur Respir J 2015, 46(3):707-716.
74. van Ingen J., Egelund E.F., Levin A., et al. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. Am J Respir Crit Care Med 2012, 186(6):559-565.
75. Clement A., Tamalet A., Leroux E., et al. Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax 2006, 61:895-902.
76. Equi A., Balfour-Lynn I.M., Bush A., et al. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002, 360:978-984.
77. Saiman L., Marshall B.C., Mayer-Hamblett N., et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003, 290:1749-1756.
78. Wolter J., Seeney S., Bell S., et al. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002, 57:212-216.
79. Wallace R.J., Brown-Elliott B.A., McNulty S., et al. Macrolide/Azalide therapy for nodular/bronchiectatic Mycobacterium avium complex lung disease. Chest 2014, 146:276-282.
80. Jeong B.H., Jeon K., Park H.Y., et al. Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2015, 191:96-103.
81. Gilljam M., Berning S.E., Peloquin C.A., et al. Therapeutic drug monitoring in patients with cystic fibrosis and mycobacterial disease. Eur Respir J 1999, 14:347-351.
82. Ebert D.L., Olivier K.N. Nontuberculous mycobacteria in the setting of cystic fibrosis. Clin Chest Med 2002, 23:655-663.
83. Cho Y.J., Yi H., Chun J., et al. The genome sequence of 'Mycobacterium massiliense' strain CIP 108297 suggests the independent taxonomic status of the Mycobacterium abscessus complex at the subspecies level. PLoS One 2013, 8:e81560.
84. Roux A.L., Catherinot E., Soismier N., OMA Group, et al. Comparing Mycobacterium massiliense and Mycobacterium abscessus lung infections in cystic fibrosis patients. J Cyst Fibros 2015, 14:63-69.
85. Kearns G.L., Trang J.M. Introduction to pharmacokinetics: aminoglycosides in cystic fibrosis as a prototype. J Pediatr 1986, 108:847-853.
86. de Groot R., Smith A.L. Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance. Clin Pharmacokinet 1987, 13:228-253.
87. Rey E., Treluyer J.M., Pons G. Drug disposition in cystic fibrosis. Clin Pharmacokinet 1998, 35:313-329.
88. Wallace R.J., Brown B.A., Griffith D.E., et al. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection. J Infect Dis 1995, 171:747-750.
89. Peloquin C.A. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002, 62:2169-2183.
90. Moriarty T.F., McElnay J.C., Elborn J.S., et al. Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection. Pediatr Pulmonol 2007, 42:1008-1017.
91. Jeon K., Kwon O.J., Lee N.Y., et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med 2009, 180:896-902.
92. Jarand J., Levin A., Zhang L., et al. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis 2011, 52:565-571.
93. Mitchell J.D. Surgical approach to pulmonary nontuberculous mycobacterial infections. Clin Chest Med 2015, 36:117-122.
94. Yu J.A., Weyant M.J., Mitchell J.D. Surgical treatment of atypical mycobacterial infections. Thorac Surg Clin 2012, 22:277-285.
95. Jonsson B.E., Gilljam M., Lindblad A., et al. Molecular epidemiology of Mycobacterium abscessus, with focus on cystic fibrosis. J Clin Microbiol 2007, 45:1497-1504.
96. Braun A.T., Merlo C.A. Cystic fibrosis lung transplantation. Curr Opin Pulm Med 2011, 17:467-472.
97. Orens J.B., Estenne M., Arcasoy S., Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation, et al. International guidelines for the selection of lung transplant candidates: 2006 update-a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006, 25:745-755.
98. Taylor J.L., Palmer S.M. Mycobacterium abscessus chest wall and pulmonary infection in a cystic fibrosis lung transplant recipient. J Heart Lung Transplant 2006, 25:985-988.
99. Zaidi S., Elidemir O., Heinle J.S., et al. Mycobacterium abscessus in cystic fibrosis lung transplant recipients: report of 2 cases and risk for recurrence. Transpl Infect Dis 2009, 11:243-248.
100. Sanguinetti M., Ardito F., Fiscarelli E., et al. Fatal pulmonary infection due to multidrug-resistant Mycobacterium abscessus in a patient with cystic fibrosis. J Clin Microbiol 2001, 39:816-819.
101. Flume P.A., Egan T.M., Paradowski L.J., et al. Infectious complications of lung transplantation. Impact of cystic fibrosis. Am J Respir Crit Care Med 1994, 149:1601-1607.
102. Gilljam M., Schersten H., Silverborn M., et al. Lung transplantation in patients with cystic fibrosis and Mycobacterium abscessus infection. J Cyst Fibros 2010, 9:272-276.
103. Lobo L.J., Chang L.C., Esther C.R., et al. Lung transplant outcomes in cystic fibrosis patients with pre-operative Mycobacterium abscessus respiratory infections. Clin Transplant 2013, 27:523-529.
104. Qvist T., Pressler T., Thomsen V.O., et al. Nontuberculous mycobacterial disease is not a contraindication to lung transplantation in patients with cystic fibrosis: a retrospective analysis in a Danish patient population. Transplant Proc 2013, 45:342-345.
105. Watkins R.R., Lemonovich T.L. Evaluation of infections in the lung transplant patient. Curr Opin Infect Dis 2012, 25:193-198.
106. Bange F.C., Brown B.A., Smaczny C., et al. Lack of transmission of Mycobacterium abscessus among patients with cystic fibrosis attending a single clinic. Clin Infect Dis 2001, 32:1648-1650.
107. Harris K.A., Kenna D.T.D., Blauwendraat C., et al. Molecular fingerprinting of Mycobacterium abscessus strains in a cohort of pediatric cystic fibrosis patients. J Clin Microbiol 2012, 50:1758-1761.
108. Bryant J.M., Harris S.R., Parkhill J., et al. Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study. Lancet Respir Med 2013, 1:786-792.
109. Aitken M.L., Limaye A., Pottinger P., et al. Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center. Am J Respir Crit Care Med 2012, 185:231-232.
110. Harris K.A., Underwood A., Kenna D.T., et al. Whole-genome sequencing and epidemiological analysis do not provide evidence for cross-transmission of Mycobacterium abscessus in a cohort of pediatric cystic fibrosis patients. Clin Infect Dis 2015, 60:1007-1016.
111. Saiman L., Siegel J.D., LiPuma J.J., et al. Infection prevention and control guideline for cystic fibrosis: 2013 update. Infect Control Hosp Epidemiol 2014, 35(Suppl 1):S1-S67.
112. Ballarino G.J., Olivier K.N., Claypool R.J., et al. Pulmonary nontuberculous mycobacterial infections: antibiotic treatment and associated costs. Respir Med 2009, 103:1448-1455.